Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]- 3-E-[2-(pyridin-2-yl)ethenyl]indazole

Details for Australian Patent Application No. 2005300317 (hide)

Owner Pfizer Inc.

Inventors Zook, Scott Edward; Wu, Zhen Ping; Kania, Robert Steven; Hart, Ryan Marshal; Ouellette, Michael; Ye, Qiang

Agent Allens Arthur Robinson

Pub. Number AU-A-2005300317

PCT Pub. Number WO2006/048751

Priority 60/624,665 02.11.04 US

Filing date 21 October 2005

Wipo publication date 11 May 2006

International Classifications

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4439 (2006.01)

A61P 31/00 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

5 April 2007 PCT application entered the National Phase

  PCT publication WO2006/048751 Priority application(s): WO2006/048751

19 November 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005300329-Polyamine compositions

2005300315-CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer